Related Experiment Video
Updated: Jun 19, 2025
13:21
Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017
9.9K
Identification of Novel DNA Methylation Prognostic Biomarkers for AML With Normal Cytogenetics
Cândida Cardoso1,2, Daniel Pestana1,2, Sreemol Gokuladhas3
1Faculdade de Medicina e Ciências Biomédicas (FMCB), Universidade do Algarve/Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Faro, Portugal.
JCO Clinical Cancer Informatics
|July 25, 2024
Summary
DNA methylation markers can improve risk stratification for cytogenetically normal acute myeloid leukemia (CN-AML). A nine-CpG panel accurately predicts survival and remission, paving the way for personalized AML treatments.
Area of Science:
- Hematologic Oncology
- Epigenetics
- Genomic Medicine
Background:
- Acute myeloid leukemia (AML) is a heterogeneous cancer with variable outcomes.
- Current risk stratification for AML lacks routine integration of DNA methylation data.
- Cytogenetically normal AML (CN-AML) is often classified as intermediate-risk, necessitating refined prognostic tools.
Purpose of the Study:
- To identify DNA methylation markers for improved risk stratification in CN-AML patients.
- To develop a prognostic biomarker panel for CN-AML based on DNA methylation patterns.
Main Methods:
- Analysis of DNA methylation profiles from whole blood (n=77) and bone marrow (n=79) samples from CN-AML patients.
- Utilized 450K and 27K array platforms for CpG site assessment and survival prediction.
- Validated prognostic potential of identified CpG sites in an independent dataset.
Main Results:
- Identified 2,549 CpG sites distinguishing intermediate-poor from intermediate-favorable prognosis in CN-AML.
- Validated nine CpG sites with significant 2-year survival prediction.
- Developed an 8-CpG Somatic Panel and cg23947872 methylation status biomarker panel with strong predictive ability for survival and remission.
Conclusions:
- DNA methylation profiling offers a promising strategy for enhancing CN-AML risk stratification.
- The validated biomarker panel can aid in predicting patient outcomes.
- This approach may facilitate more personalized treatment strategies for CN-AML patients.
